The Canadian Agency for Drugs and Technologies in Health (CADTH) has released the following report.
November 13, 2009
Health Technology Assessment
Long-acting Beta2-Agonist (LABA) and Inhaled Corticosteroid (ICS) Combination Therapy for Adult Persistent Asthma: Systematic Review of Clinical Outcomes and Economic Evaluation
CADTH’s health technology assessment report on long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination therapy examines the clinical efficacy, safety, and cost-effectiveness of this treatment strategy for adult persistent asthma. This assessment focuses on LABA-ICS combination therapy and its place in therapy. The report also looks at current clinical practice guidelines and the health services impact of different treatment options.